Immuneering Corporation Reports Positive Phase 2 Results for Atebimetinib in Pancreatic…
What happened
Immuneering Corporation announced that its drug atebimetinib showed excellent results in Phase 2 clinical trials for first-line pancreatic cancer when combined with chemotherapy, achieving a median overall survival of 17.3 months. The drug is currently being evaluated in a Phase 3 trial for this condition and new preclinical findings support its use in cancers like anaplastic thyroid cancer.
From manilatimes.net
Why it matters
The positive clinical results and preclinical support for atebimetinib suggest potential for the drug across a wide range of cancer types. This clinical progress could prompt changes in investment analysis and ratings for financial services firms.
From manilatimes.net
Who's involved
- Cantor FitzgeraldAmerican financial services company that may adjust investment ratings based on clinical results
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Cantor FitzgeraldSpeculative
Might adjust investment analysis or ratings based on the positive clinical data for atebimetinib